Study of MAG-CPT, a New Cancer Drug
Author Information
Author(s): Schoemaker N E, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Porro M Grazia, Beijnen J H, Schellens J H M, ten Bokkel Huinink W W
Primary Institution: Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute
Hypothesis
Can MAG-CPT, a polymer conjugate of camptothecin, improve the pharmacokinetics and reduce toxicity in cancer treatment?
Conclusion
MAG-CPT showed controlled prolonged exposure of camptothecin but resulted in serious bladder toxicity.
Supporting Evidence
- The maximum tolerated dose was determined to be 68 mg/m²/day.
- Serious bladder toxicity was observed, which was dose-limiting.
- Pharmacokinetics showed that both bound and free camptothecin had similar half-lives.
- Haematological toxicity was relatively mild in the study.
- Patients experienced sustained dysuria and haematuria at higher dose levels.
Takeaway
Researchers tested a new cancer drug called MAG-CPT to see if it could help patients without causing too much harm, but it ended up causing some serious bladder problems.
Methodology
Patients with malignant solid tumors received MAG-CPT as a 30-minute infusion over 3 consecutive days every 4 weeks, with dose escalation to determine the maximum tolerated dose and pharmacokinetics.
Potential Biases
Potential bias due to the small number of evaluable patients for efficacy and the nature of the patient population.
Limitations
The study had a small sample size and many patients were heavily pre-treated, limiting the ability to assess efficacy.
Participant Demographics
Patients with malignant solid tumors, aged 18 or older, with a WHO performance status of 2 or less.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website